Benzinga··Vandana SinghNovo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial
Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss